Oral Proteins & Peptides Market: Growth, Size, Share, and Trends

Report Code PH 9204
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

Overview

The market for oral proteins and peptides is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% from 2024 to 2029. Market growth is attributed to factors such as the increasing prevalence of chronic diseases (such as diabetes and gastroenterology & kidney diseases), advancements in drug delivery technologies, and patient preference & compliance for the oral route of drug administration. Semaglutide, a GLP-1 receptor agonist, accounted for the major share in the market due to the increasing prevalence of diabetes, obesity, and overweight. Novo Nordisk A/S (Denmark) also announced the development of another GLP-1 receptor agonist molecule for treating obesity and overweight.

Attractive Opportunities in the Oral Proteins and Peptides Market

North America

Growth in the North American market can be attributed to the growing investments in research for developing oral peptides and their growing adoption in the region.

Growth in the market is mainly driven by the increasing focus on innovation to develop new oral proteins and peptides and a high demand for these drugs.

Growing use in new therapeutic indications (NASH, Alzheimer’s disease, etc.) is a key opportunity area for players in the oral proteins and peptides market.

The high cost of drug development and a stringent regulatory approval process may restrain market growth over the forecast period.

Globally, North America is the largest market for oral proteins and peptides, and this trend is expected to continue during the forecast period.

Global Oral Proteins and Peptides Market Dynamics

DRIVER: Rising Prevalence of Chronic Diseases

Chronic diseases like diabetes, heart disease, stroke, and cancer are some major causes of morbidity and mortality. After improvements in public health systems, disease trends shifted, and the prevalence of chronic diseases began to grow, incurring increasing costs. The Mayo Clinic estimated the chronic disease burden at USD 47 trillion worldwide by 2030. These diseases are gaining ground due to increasingly evident risk factors: physical inactivity, poor nutrition, tobacco use, and excessive alcohol consumption. In the US, the CDC estimated that 90% of the country’s USD 4.5 trillion annual healthcare expenditure was incurred by chronic and mental health conditions. Thus, several oral peptides have been launched for this segment, such as RYBELSUS (Semaglutide) for type 2 diabetes, DAYBUE (Trofinetide) for Rett Syndrome, LUPKYNIS (Voclosporin) for lupus nephritis, and TRULANCE (Plecanatide) for chronic idiopathic constipation and IBS with constipation.

RESTRAINT: High Cost is Associated With Drug Development

The costs required for developing these new therapies are high and represent an important restraint to their adoption and availability. Oral proteins and peptides have major challenges: poor intestinal absorption and enzymatic degradation in the GI tract. There is a desire to develop formulations that protect these molecules from the different harsh conditions of the stomach and improve their bioavailability. Examples include enteric coatings, permeation enhancers, and nanoparticle carriers; however, these are also advanced and costly technologies. Other technologies that add a tremendous cost to drug development are liposomes, micelles, and nano-encapsulation because these systems are designed to enhance stability and absorption and involve expensive research, testing, and manufacturing processes. Thus, the cost of the development, manufacturing, and market introduction of oral proteins and peptides limits the growth of the market.

 

OPPORTUNITY: Robust Clinical Trial Pipeline for Oral Proteins and Peptides

A significant clinical trial pipeline for oral proteins and peptides exists, bolstered by growing drug delivery technologies and the demand for treatments that do not require injections. These therapies may improve patient compliance and expand the range of conditions that could be medically managed using orally delivered proteins and peptides. The current clinical pipeline includes drugs designed to address obesity & overweight, hormonal disorders, plaque, and psoriasis. The variety extends oral peptides beyond traditional areas to new revenue streams. In addition, new oral peptide drugs, such as the oral GLP-1 receptor agonist Semaglutide, are said to deliver promising results in clinical studies. Such innovation would open up the possibility of oral alternatives for other peptide drugs with broader applications. The pipeline includes drugs exploiting advanced technologies, including enteric coatings, mucoadhesive systems, nanoparticle carriers, and permeation enhancers to enhance the stability and absorption of oral proteins and peptides. These technologies are streamlined and further perfected through clinical trials.

CHALLENGES: Maintaining Formulations and Stability

The formulation and stability of oral proteins and peptides represent one of the largest challenges for the growth of this market. Proteins and peptides are huge, complex molecules that are sensitive to environmental conditions, making their development as oral drugs more challenging. The GI tract also contains several proteolytic enzymes that include pepsin in the stomach and trypsin and chymotrypsin in the small intestine. These enzymes break proteins and peptides into small, inactive fragments, greatly reducing the bioavailability of orally administered proteins. Molecular lengths of proteins and peptides are long, and they are hydrophilic; hence, penetration into the intestinal epithelium through the lipophilic cell membranes is almost impossible. This low permeability results in little or no absorption into the bloodstream. Poor absorption, combined with a huge amount of degradation, requires a relatively higher dose to achieve the desired therapeutic effect in oral proteins and peptides and thus raises the possibility of side effects and manufacturing costs.

Global Oral Proteins and Peptides Market Ecosystem Analysis

The oral proteins and peptides market ecosystem comprises raw material suppliers providing essential components like API and excipient manufacturers and end users such as hospitals & specialty clinics, long-term facilities, and home care settings. Manufacturers develop and distribute oral proteins and peptides while navigating regulations set by bodies like the FDA and the EMA. Raw material suppliers provide critical components such as APIs and biochemicals for developing oral proteins and peptides.

 

The glucagon-like peptide-1 (GLP-1) receptor agonist segment dominated the market, by drug class, in 2023.

The drug class segmentation includes analogs of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and others. In 2023, the GLP-1 receptor agonist segment accounted for the largest market share. These drugs are designed to mimic the incretin hormone glucagon-like peptide-1 (GLP-1). They form part of a class of drugs called incretin mimetics. In clinical practice, these drugs have been used predominantly for type 2 diabetes mellitus, but they have recently become integral to the treatment and management of obesity and overweight.

By end user, home care settings are expected to register the highest growth.

Based on end users, the oral proteins and peptides market is segmented into home care settings, long-term care facilities, and hospitals & specialty clinics. In 2023, the home care settings segment is expected to grow at the highest CAGR. The main drivers for this end-user segment include the increasing awareness and adoption of these drugs, their ease of use, and efficacy in treating target ailments (such as diabetes, gastric diseases like IBD & constipation, and central nervous system disorders). Studies have also shown that patient compliance is significantly higher for the oral route of administration and in home care settings.

North America was the largest regional market for the oral proteins and peptides market in 2023.

The global market for oral proteins and peptides is studied for North America, the Asia Pacific, Europe, Latin America, the Middle East, and Africa. North America was the largest segment of the oral proteins and peptides market in 2023, followed by Europe and the Asia Pacific. The presence of key market players such as AbbVie (US) & Pfizer (US), the increasing approval of oral proteins and peptide products in North America, the availability of government funding for life science research, advances in drug delivery techniques, and growth in the pharmaceutical & biopharmaceutical industries have made North America the largest regional market for oral proteins and peptides.

HIGHEST CAGR MARKET IN 2024
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION

Recent Developments of Oral Proteins and Peptides Market

  • In September 2023, EnteraBio entered a research collaboration agreement with OPKO Biologics, Inc. Under the terms of this agreement, OPKO has agreed to supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs for developing oral tablet formulations.
  • In April 2023, Chiesi Farmaceutici S.p.A. acquired Amryt Pharma, a commercial-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. Mycapssa (octreotide capsules) is a brand of Amryt Pharma.
  • In October 2022, Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of oral peptide NURTEC ODT (rimegepant), an innovative migraine therapy approved for acute treatment and prevention of episodic migraine in adults.
  • In December 2023, Pfizer received approval form Health Canada for NURTEC ODT (rimegepant) for treating acute migraine.

Key Market Players

KEY PLAYERS IN THE ORAL PROTEINS AND PEPTIDES MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Oral Proteins & Peptides Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD)
Segments covered Molecule, Drug Class, Therapeutic Area, Formulation, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

Key Questions Addressed by the Report

Who are the key players in the oral proteins and peptides market?
Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), and Pfizer Inc. (US).
Which molecule segment dominates the oral proteins and peptides market?
Semaglutide dominated the oral proteins and peptides market, by molecule. Its large share can be attributed to the increasing prevalence of diabetes and R&D to expand its indications.
Which drug class segment of the oral proteins and peptides market accounted for the largest market share?
In 2023, the GLP-1 receptor agonist drug class segment accounted for the largest market share. The large share is attributed to the robust clinical trial pipeline for GLP-1 drug candidates.
Which therapeutic area segment of the oral proteins and peptides market accounted for the largest market share?
In 2023, diabetes held the largest market share, by therapeutic area. The large share of this segment can be attributed to the increasing approval of oral proteins and peptides for diabetes.
What is the market size for the oral proteins and peptides market?
The oral proteins and peptides market is expected to grow at a CAGR of 22.5% during the forecast period. The market is estimated to be around USD 7.38 billion in 2024 and is projected to reach USD 20.36 billion by 2029.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Oral Proteins & Peptides Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
32
RESEARCH METHODOLOGY
36
EXECUTIVE SUMMARY
46
PREMIUM INSIGHTS
51
MARKET OVERVIEW
54
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing burden of chronic diseases
    - Advancements in drug delivery technologies
    - Higher patient compliance and preference for oral route
    - Expanding therapeutic applications of oral proteins & peptides
    RESTRAINTS
    - High cost of drug development
    - Contraindication of oral proteins & peptides
    - Stringent regulatory approval process
    OPPORTUNITIES
    - Robust clinical trial pipeline for oral proteins & peptides
    - Growing demand for personalized medicine
    CHALLENGES
    - Hurdles in formulation and stability
    - Availability of alternative therapies
  • 5.3 ECOSYSTEM ANALYSIS
    ROLE OF RAW MATERIAL VENDORS
    ROLE OF PRODUCT PROVIDERS
    ROLE OF END USERS
    ROLE OF REGULATORY AUTHORITIES
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS
    BUYING CRITERIA
  • 5.8 PRICING ANALYSIS
    PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS
    PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION
  • 5.9 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.11 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Transient permeation enhancer
    - Gastrointestinal permeation enhancement technology
    - Oral sCT (OSTORA) technology
    COMPLEMENTARY TECHNOLOGIES
    - Peptelligence
    - ThioMatrix
    - Transferrin-based recombinant fusion protein
    ADJACENT TECHNOLOGIES
    - Oramed and Orasome
    - Q-sphera
    - Nanoinclusion
    - Oleotec and Soctec
  • 5.12 PIPELINE ANALYSIS
  • 5.13 PATENT ANALYSIS
    METHODOLOGY
    INNOVATION AND PATENT APPLICATIONS
    TOP APPLICANTS
  • 5.14 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
87
  • 6.1 INTRODUCTION
  • 6.2 SEMAGLUTIDE
    INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
  • 6.3 CALCITONIN
    NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
  • 6.4 LINACLOTIDE
    RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
  • 6.5 TROFINETIDE
    FDA APPROVAL TO SUPPORT GROWTH
  • 6.6 VOCLOSPORIN
    INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
  • 6.7 PLECANATIDE
    INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
  • 6.8 OTHER MOLECULES
ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
107
  • 7.1 INTRODUCTION
  • 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
    INCREASING ADOPTION TO SUPPORT GROWTH
  • 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
    INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
  • 7.4 GUANYLATE CYCLASE-C AGONISTS
    RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET
  • 7.5 GLYCINE-PROLINE-GLUTAMATE
    FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
  • 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
    INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
  • 7.7 OTHER DRUG CLASSES
ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
125
  • 8.1 INTRODUCTION
  • 8.2 DIABETES
    HIGH EFFICACY TO SUPPORT END-USER ADOPTION
  • 8.3 CNS DISORDERS
    GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
  • 8.4 GASTROENTEROLOGY
    RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
  • 8.5 GENETIC DISORDERS
    GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
  • 8.6 NEPHROLOGY
    RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
  • 8.7 OBESITY & OVERWEIGHT
    RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
  • 8.8 OTHER THERAPEUTIC AREAS
ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
146
  • 9.1 INTRODUCTION
  • 9.2 TABLETS
    HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
  • 9.3 CAPSULES
    RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
  • 9.4 ORAL SOLUTIONS
    GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH
    ORAL PROTEINS & PEPTIDES MARKET, BY END USER
ORAL PROTEINS & PEPTIDES MARKET, BY END USER
147
  • 10.1 INTRODUCTION
  • 10.2 HOME CARE SETTINGS
    RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
  • 10.4 HOSPITALS & SPECIALTY CLINICS
    ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
ORAL PROTEINS & PEPTIDES MARKET, BY REGION
167
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
    US
    - US to hold large share of North American and global markets
    CANADA
    - Increasing prevalence of obesity and heart failure to support market growth
  • 11.3 EUROPE
    EUROPE: MACROECONOMIC OUTLOOK
    GERMANY
    - Germany to hold largest share of European market
    UK
    - Strong focus on advancement of life sciences to support market growth
    FRANCE
    - Growing prevalence of diabetes and government initiatives to boost market growth
    ITALY
    - Presence of major pharmaceutical and biotechnology companies to drive market
    SPAIN
    - Initiatives associated with GLP-1 drugs to drive market
    NETHERLANDS
    - Rising awareness and focus on pharmaceutical R&D to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: MACROECONOMIC OUTLOOK
    CHINA
    - Increasing R&D expenditure to drive market
    JAPAN
    - Increasing prevalence of diabetes to drive market
    INDIA
    - Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
    AUSTRALIA
    - Rising access to GLP-1 drugs and government support to drive market
    SOUTH KOREA
    - Growing focus on development of innovative treatment solutions to propel market growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: MACROECONOMIC OUTLOOK
    BRAZIL
    - Brazil to hold largest market share in Latin America
    MEXICO
    - Growing diabetes and obesity cases to support market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MIDDLE EAST: MACROECONOMIC OUTLOOK
    GCC COUNTRIES
    - Saudi Arabia
    - UAE
    - Rest of GCC countries
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
    AFRICA: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
248
  • 12.1 OVERVIEW
  • 12.2 KEY STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company Footprint
    - Molecule footprint
    - Formulation footprint
    - Therapeutic area footprint
    - Region footprint
  • 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 12.8 VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.9 BRAND/PRODUCT COMPARISON
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
272
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYERS
    NOVO NORDISK A/S
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ABBVIE INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    PFIZER INC.
    - Business overview
    - Product pipeline
    - Recent developments
    - MnM view
    BAUSCH HEALTH COMPANIES INC.
    - Business overview
    - Products offered
    - Recent developments
    CHIESI FARMACEUTICI S.P.A.
    - Business overview
    - Products offered
    - Recent developments
    ACADIA PHARMACEUTICALS INC.
    - Business overview
    - Products offered
    - Recent developments
    AURINIA PHARMACEUTICALS INC.
    - Business overview
    - Products offered
    - Recent developments
    MERCK & CO., INC.
    - Business overview
    - Product pipeline
    - Recent developments
    JOHNSON & JOHNSON SERVICES, INC.
    - Business overview
    - Product pipeline
    - Recent developments
    SWK HOLDINGS
    - Business overview
    - Product pipeline
    - Recent developments
    R-PHARM JSC
    - Business overview
    - Products in pipeline
    ENTERA BIO LTD.
    - Business overview
    - Product pipeline
    - Recent developments
    PROXIMA CONCEPTS
    - Business overview
    - Products in pipeline
  • 13.3 OTHER PLAYERS
    ASTRAZENECA PLC
    REGOR THERAPEUTICS GROUP
    TERNS PHARMACEUTICALS, INC.
    STRUCTURE THERAPEUTICS
    VIKING THERAPEUTICS
    PROTAGONIST THERAPEUTICS INC.
    RANI THERAPEUTICS
    CARMOT THERAPEUTICS, INC.
    ZEALAND PHARMA
    SCIWIND BIOSCIENCES CO., LTD.
    JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
APPENDIX
311
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS
TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS
TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS
TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS
TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER
TABLE 8 PRICING ANALYSIS, BY PRODUCT, 2024
TABLE 9 PRICING ANALYSIS, BY COUNTRY AND REGION (USD), 2024
TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF AUGUST 2024)
TABLE 16 ORAL PROTEINS & PEPTIDES MARKET: TOP 20 PATENT OWNERS, 2014–2024
TABLE 17 INDICATIVE LIST OF PATENTS IN ORAL PROTEINS & PEPTIDES MARKET, 2022–2024
TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 19 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 20 SEMAGLUTIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 21 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 CALCITONIN MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 28 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 LINACLOTIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 TROFINETIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 VOCLOSPORIN MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 49 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 PLECANATIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 53 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 58 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 60 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 65 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 67 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 68 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 73 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 80 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 GC-C AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 87 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 GPE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 EUROPE: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 MIDDLE EAST: GPE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 94 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 CNI MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 EUROPE: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 107 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2022–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 115 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 122 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2022–2029 (USD MILLION)
TABLE 140 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 141 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 144 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 147 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 151 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 156 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 157 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 159 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 162 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 166 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 167 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 171 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 172 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 173 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD MILLION)
TABLE 174 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD MILLION)
TABLE 179 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 181 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 186 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 188 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 193 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: MACROECONOMIC OUTLOOK
TABLE 196 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 198 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 199 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 200 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 202 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 203 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 204 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 205 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 206 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 207 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 208 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 209 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 210 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 211 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 212 EUROPE: MACROECONOMIC OUTLOOK
TABLE 213 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 214 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 215 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 216 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 217 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 219 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 220 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 221 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 222 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 223 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 224 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 225 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 226 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 227 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 228 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 229 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 230 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 231 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 232 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 233 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 234 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 235 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 236 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 237 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 238 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 239 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 240 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 241 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 242 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 243 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 244 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 245 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 246 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 247 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 248 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 249 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 250 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 251 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 252 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 253 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 254 ASIA PACIFIC: MACROECONOMIC OUTLOOK
TABLE 255 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 256 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 257 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 258 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 259 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 261 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 262 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 263 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 264 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 265 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 266 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 267 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 268 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 269 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 270 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 271 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 272 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 273 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 274 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 275 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 276 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 277 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 278 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 279 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 280 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 281 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 282 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 283 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 284 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 285 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 291 LATIN AMERICA: MACROECONOMIC OUTLOOK
TABLE 292 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 293 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 294 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 295 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 296 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 298 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 299 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 300 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 301 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 302 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 303 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 304 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 305 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 306 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 307 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 308 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 309 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 310 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 311 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 312 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 313 MIDDLE EAST: MACROECONOMIC OUTLOOK
TABLE 314 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 315 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 316 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 317 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 318 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 320 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 321 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 322 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 323 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 324 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,2022–2029 (USD MILLION)
TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 326 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 327 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 328 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 329 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 330 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 331 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 332 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 333 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 334 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 335 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 336 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 337 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 338 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 339 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 340 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 341 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 342 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 343 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 344 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 345 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 346 AFRICA: MACROECONOMIC OUTLOOK
TABLE 347 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION)
TABLE 348 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
TABLE 349 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 350 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION)
TABLE 351 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 352 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
TABLE 353 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION
TABLE 354 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS)
TABLE 355 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS)
TABLE 356 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (KEY PLAYERS)
TABLE 357 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS)
TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: KEY STARTUPS/SMES
TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS, JANUARY 2021– AUGUST 2024
TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021–AUGUST 2024
TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021– AUGUST 2024
TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS, JANUARY 2021– AUGUST 2024
TABLE 366 NOVO NORDISK: COMPANY OVERVIEW
TABLE 367 NOVO NORDISK: PRODUCTS OFFERED
TABLE 368 NOVO NORDISK: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024
TABLE 369 NOVO NORDISK: EXPANSIONS, JANUARY 2021– AUGUST 2024
TABLE 370 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021– AUGUST 2024
TABLE 371 ABBVIE: COMPANY OVERVIEW
TABLE 372 ABBVIE: PRODUCTS OFFERED
TABLE 373 ABBVIE: PRODUCT APPROVALS, JANUARY 2021– AUGUST 2024
TABLE 374 PFIZER: COMPANY OVERVIEW
TABLE 375 PFIZER: PRODUCT PIPELINE
TABLE 376 PFIZER: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024
TABLE 377 PFIZER: DEALS, JANUARY 2021–AUGUST 2024
TABLE 378 PFIZER: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
TABLE 379 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW
TABLE 380 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED
TABLE 381 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024
TABLE 382 CHIESI FARMACEUTICI: COMPANY OVERVIEW
TABLE 383 CHIESI FARMACEUTICI: PRODUCTS OFFERED
TABLE 384 CHIESI FARMACEUTICI: DEALS, JANUARY 2021–AUGUST 2024
TABLE 385 ACADIA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 386 ACADIA PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 387 ACADIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024
TABLE 388 AURINIA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 389 AURINIA PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 390 AURINIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024
TABLE 391 MERCK & CO.: COMPANY OVERVIEW
TABLE 392 MERCK & CO.: PRODUCT PIPELINE
TABLE 393 MERCK & CO.: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
TABLE 394 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW
TABLE 395 JOHNSON & JOHNSON SERVICES: PRODUCT PIPELINE
TABLE 396 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2021– AUGUST 2024
TABLE 397 SWK HOLDINGS: COMPANY OVERVIEW
TABLE 398 SWK HOLDINGS: PRODUCT PIPELINE
TABLE 399 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
TABLE 400 R-PHARM JSC: COMPANY OVERVIEW
TABLE 401 R-PHARM JSC: PRODUCTS IN PIPELINE
TABLE 402 ENTERA BIO: COMPANY OVERVIEW
TABLE 403 ENTERA BIO: PRODUCT PIPELINE
TABLE 404 ENTERA BIO: DEALS, JANUARY 2021–AUGUST 2024
TABLE 405 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
TABLE 406 PROXIMA CONCEPTS: COMPANY OVERVIEW
TABLE 407 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE
LIST OF FIGURES
 
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
FIGURE 5 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 7 CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2024–2029
FIGURE 8 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
FIGURE 12 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
FIGURE 13 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET
FIGURE 16 INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH
FIGURE 17 TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
FIGURE 18 DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 19 HOME CARE SETTINGS TO DOMINATE MARKET TILL 2029
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 21 ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS
FIGURE 23 ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS
FIGURE 24 ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 25 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES
FIGURE 27 KEY BUYING CRITERIA FOR END USERS
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 29 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
FIGURE 30 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
FIGURE 31 ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 32 NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 33 EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2021–2023 (USD MILLION)
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2023)
FIGURE 36 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 37 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
FIGURE 38 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
FIGURE 39 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
FIGURE 40 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 43 ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 44 NOVO NORDISK: COMPANY SNAPSHOT
FIGURE 45 ABBVIE: COMPANY SNAPSHOT
FIGURE 46 PFIZER: COMPANY SNAPSHOT
FIGURE 47 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT
FIGURE 48 CHIESI FARMACEUTICI: COMPANY SNAPSHOT
FIGURE 49 ACADIA PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 50 AURINIA PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 51 MERCK & CO.: COMPANY SNAPSHOT
FIGURE 52 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT
FIGURE 53 SWK HOLDINGS: COMPANY SNAPSHOT

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Bottom-up approach were used to estimate and validate the total size of the oral proteins and peptides market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The list of approved oral proteins and peptides was identified through extensive secondary and primary research. 
  • The oral proteins and peptides products in pipeline were identified from clinical trial registries, secondary and primary research for drug classes of peptide and protein therapeutics.
  • The revenues generated from these oral proteins and peptides have been determined through annual reports, and secondary sources (including paid database)
  • The products were mapped as per the segments of the market. Percentage shares, splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts
  • All assumptions, approaches and individual shares/revenue estimates were validated through expert interviews.

Global Oral Proteins and Peptides Market Size: Bottom-up Approach

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Oral Proteins and Peptides refer to therapeutic drugs composed of proteins or peptides (short chains of amino acids) that are intended to be administered orally. These biologically active molecules are designed to treat various medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Specialty clinics
  • Long term care facilities
  • Patient advocacy organizations
  • Academic researchers and government research organizations
  • Private research institutes
  • Contract manufacturing organizations (CMOs)
  • Contract research organizations (CROs)
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
  • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Oral Proteins & Peptides Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status